Clinical Trials: Rare Disease
Summary
Understand the clinical trial landscape of rare disease trials.
Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Reasons to Buy
- Identify key analysis and segmentation of rare disease trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and decentralized clinical trial use.
- 1. Tables and Figures
- 2. Executive Summary
- 3. Introduction
- 4. Rare Disease
- 5. Key Findings
- 6. Appendix
- List of Figures
- Figure 1: Number of rare disease trials, by year (2004-24)
- Figure 2: Rare disease trials, by regional distribution (2004-24)
- Figure 3: Number of rare disease trials, by top five countries (2004-24)
- Figure 4: Rare disease clinical trials, by year and phase (2004-24)
- Figure 5: Top 10 TAs in rare disease clinical trials, by phase
- Figure 6: Rare disease clinical trials, by sponsor type (2004-24)
- Figure 7: Rare disease trials, by top 10 non-industry sponsors
- Figure 8: Rare disease trials, by top 10 industry sponsors
- Figure 9: Terminated/suspended/withdrawn rare disease trials, by leading sponsors
- Figure 10: Rare disease clinical trials, by leading CROs
- Figure 11: Single-country & multinational rare disease trials, by region (2004-24)
- Figure 12 and 13: Rare disease clinical trials, by reason for termination and terminations by trial phase
- Figure 14 and 15: Number of rare disease clinical trials, by virtual components
- Figure 16 and 17: Rare disease clinical trials, by trial status and endpoint status
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook